Description: Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.
Home Page: www.calithera.com
CALA Technical Analysis
343 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 870 1000
Officers
| Name | Title |
|---|---|
| Dr. Susan M. Molineaux Ph.D. | Founder, CEO, Pres & Director |
| Ms. Stephanie Wong | CFO & Sec. |
| Dr. Eric B. Sjogren | Sr. VP of Drug Discovery |
| Dr. Christopher J. Molineaux Ph.D. | Sr. VP of Devel. |
| Mr. Frank Parlati Ph.D. | Sr. VP of Research |
| Dr. Emil T. Kuriakose M.D. | Chief Medical Officer |
| Dr. Susan B. Demo Ph.D. | Sr. VP of R&D Operations |
| Dr. Allison Dillon Ph.D. | Sr. VP of Commercial & Portfolio Strategy |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8639 |
| Price-to-Sales TTM: | 1.7108 |
| IPO Date: | 2014-10-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 63 |